linjc16/ctgov huggingface dataset:
Yoga for Treating Shortness of Breath in Chronic Obstructive Pulmonary Disease (COPD)

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate the safety and effectiveness of yoga in reducing shortness of breath in people with chronic obstructive pulmonary disease (COPD). Patients in this study must have moderate to severe COPD and be primarily limited by shortness of breath.

Detailed Description
-----------------
Management of dyspnea (shortness of breath) is a major concern for patients with COPD. The efficacy of complementary exercises to manage dyspnea is unknown. Complementary exercises may be more congruent with patients' lifestyles and values than traditional exercise programs and can be adapted to changes in illness severity and disability. Yoga practice is a complementary therapy that people use to manage their dyspnea. The aims of this study are to: 1) develop a safe and feasible yoga program for patients with COPD; 2) test the efficacy of this program; and 3) determine whether physical performance, psychological well being, and health-related quality of life are positively affected by yoga practice. Patients in this study will be randomized to receive yoga training or usual care for 12 weeks. Patients will be evaluated at study entry, after each session, and immediately after the training program.

Official Title
-----------------
Efficacy of Yoga for Self-Management of Dyspnea in COPD

Conditions
-----------------
Pulmonary Disease, Chronic Obstructive, Lung Diseases, Obstructive, Pulmonary Emphysema, Chronic Bronchitis

Intervention / Treatment
-----------------
* Behavioral: yoga


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria: Able to commit to a 12-week yoga class in San Francisco, California Moderate to severe COPD, clinically stable for at least 1 month prior to study entry Forced Expiratory Volume at one minute (FEV1) < 49% predicted after inhaled bronchodilator Activities of daily living limited by shortness of breath Ability to speak English and sign consent Patients receiving supplemental oxygen will be acceptable if their O2 saturation can be maintained at > 85% on < 6 L/min of nasal oxygen Exclusion criteria: Symptomatic illness (e.g., cancer, left heart failure, ischemic heart disease, neuromuscular disease, psychiatric illness) Formal pulmonary rehabilitation training within 1 year prior to study entry

Ages Eligible for Study
-----------------
Minimum Age: 40 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Behavioral: yoga|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Mechanisms of Infertility and Hormonal Changes in Patients With Chronic Kidney Disease

Study Overview
=================
Brief Summary
-----------------
Patients with chronic kidney disease (both men and women), especially those with terminal renal failure, manifest infertility. There has been demonstrated several hormonal changes in patients on dialysis. Increased levels of luteinizing hormone (LH) has been seen in men (12). In women the opposite has been reported. The number of spermatocytes is reduced and a disturbance in maturation has been observed. This project is aimed to study the influence of uremic milieu on fertility in men and women. The hypopituitary/hypothalamus gland axis and hormonal levels will be studied.

Detailed Description
-----------------
Renal elimination of hormones and peptides. By using a human transplantation model the investigators will study changes in hormonal levels before and after a successful transplantation up to 12 months. Hormones: testosterone, SHBG (sex hormone binding globulin), LH (luteinizing hormone), FSH (follicle stimulating hormone), estradiol and inhibin B. Analysis of sperm quality, concentration, motility, morphology and as well DNA-fragmentation index (DFI) in men with chronic kidney disease. In women the investigators will study the maturation of follicles via vaginal ultrasound. Controls are persons from a study at Dept of Reproductive Medicine.

Official Title
-----------------
Studies of Infertility in Patients With Chronic Kidney Disease

Conditions
-----------------
Infertility

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: GFR-levels Exclusion Criteria: > 50 years old

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| renal transplant patients<br>Patients undergoing transplantation | |
| dialysis patients<br>hemodialysis patients and peritoneal dialysis patients. Before and after a dialysis session | |
| patients with renal insufficiency<br>outpatient patients with chronic kidney disease stage 2, 3 and 4 | |
| Chronic kidney disease<br>outpatient cohort. Those with mild renal insufficiency | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| concentration of sex hormone levels in plasma |  | up to three years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| sperm motility |  | up to three years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Hormone, Sperm, Chronic kidney disease
Effects of Tradipitant on Satiation, Gastric Volume, Gastric Accommodation, and Gastric Emptying in Healthy Volunteers

Study Overview
=================
Brief Summary
-----------------
To evaluate the effects of tradipitant relative to placebo on satiation, gastric volume, gastric accommodation, and gastric emptying in healthy volunteers.

Official Title
-----------------
VP-VLY-686-1301: A Single Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of Tradipitant on Satiation, Gastric Volume, Gastric Accommodation and Gastric Emptying in Healthy Volunteers

Conditions
-----------------
Healthy Volunteer

Intervention / Treatment
-----------------
* Drug: Tradipitant
* Drug: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Able to provide written consent Body Mass Index (BMI) of 18-35 kg/m2 No medical problems or chronic diseases Exclusion Criteria: Diagnosis of gastrointestinal diseases Structural or metabolic diseases that affect the GI system A positive test for drugs of abuse at screening

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Tradipitant<br>Oral Capsule | Drug: Tradipitant<br>* Tradipitant Capsule<br>|
| Placebo Comparator: Placebo<br>Oral Capsule | Drug: Placebo<br>* Placebo Capsule<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Fasting gastric volume as measured by single photon emission computed tomography (SPECT) |  | 9 Days | 
| Accommodation volume as measured by SPECT |  | 9 Days | 
| Satiation expressed as volume to fullness as measured by satiation test |  | 9 Days | 
| Gastric emptying half-time of solids as measured by scintigraphy |  | 9 Days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
tradipitant, NK-1 antagonist, neurokinin 1 receptor
Utility of Brain Natriuretic Peptide (BNP) in Patients With Type IV Cardio-renal Syndrome Admitted to the Intensive Care Unit (ICU)

Study Overview
=================
Brief Summary
-----------------
Admission BNP was a useful marker for diagnosing and predicting type IV cardio-renal syndrome type IV in patients with chronic kidney disease admitted to the ICU for acute heart failure in a retrospective study. Therefore, we aim to prospectively investigate the utility of serum BNP in evaluating the treatment adequacy and predicting future cardiac events in patients with type IV CRS.

Official Title
-----------------
Utility of BNP in Patients With Type IV Cardio-renal Syndrome Admitted to the ICU: a Prospective Observational Study

Conditions
-----------------
Chronic Kidney Disease, Acute Heart Failure

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adult patients aged > 18 years, Patients with chronic kidney disease (Serum Cr > 2.0, Documented medical history of chronic kidney disease Exclusion Criteria: Cardiopulmonary resuscitation, Do-not-resuscitate state, Acute kidney injury, ICU stay < 1 day

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Brain natriuretic peptide, Cardio-renal syndrome
Hydrochlorothiazide (+) Losartan Potassium vs. Amlodipine Comparative Study (0954A-314)

Study Overview
=================
Brief Summary
-----------------
An efficacy and safety study of hydrochlorothiazide (+) losartan potassium compared to amlodipine at week 12 in Korean patients with essential hypertension

Official Title
-----------------
A 12 Week, Open, Randomized, Parallel, Multicenter Study of Efficacy, Tolerability & Safety of Hydrochlorothiazide (+) Losartan Potassium Versus Amlodipine in Essential Hypertensive Patients.

Conditions
-----------------
Essential Hypertension

Intervention / Treatment
-----------------
* Drug: MK0954A; hydrochlorothiazide (+) losartan potassium / Duration of Treatment: 12 weeks


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients of age 20 70 75 with essential hypertension SiDBP 90   114mmHg at V1 & V2 Exclusion Criteria: Patient has known or suspected secondary hypertension Patient has a history of malignant hypertension (SiSBP > 210mmHg) Individuals has a known sensitivity or intolerance to HCTZ or any AIIAs, or any sulfonamide-derived drugs. Patient has shown significant abnormal laboratory evaluations

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: MK0954A; hydrochlorothiazide (+) losartan potassium / Duration of Treatment: 12 weeks|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Antihypertensive efficacy of 12 weeks of treatment with hydrochlorothiazide (+) losartan potassium/amlodipine |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Safety/Tolerability |  |  |
SURVEY ABOUT STRESS-COVID IN HEALTH CARE WORKERS IN NORTH AFRICA COUNTRY

Study Overview
=================
Brief Summary
-----------------
This study aimed to investigate the psychological impact of the COVID-19 outbreak on healthcare workers (HCWs) and to identify ways of coping with this unprecedented stressful situation.

Detailed Description
-----------------
This was a cross-sectional study based on an online questionnaire that included 62 questions (scores, 0 - 3). The chi-square (χ²) test was used to compare the responses between professional groups, age groups, and genders.

Official Title
-----------------
PSYCHOLOGICAL IMPACT, STRESS FACTORS AND BEHAVIOURS IN HEALTH CARE PROFESSIONALS DURING THE COVID-19 PANDEMIC IN TUNISIA

Conditions
-----------------
HEALTH CARE WORKERS

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: HEALTH CARE WORKERS Exclusion Criteria: no one

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| STRESS-COVID | SURVEY ABOUT STRESS-COVID IN HEALTH CARE WORKERS | 01 months |
Nutrients to Enhance Sleep Quality and Quantity

Study Overview
=================
Brief Summary
-----------------
Identifying non-pharmacological means of enhancing sleep is an important area of research for elite athletes. Research completed at the AIS has identified that some athletes have difficulties falling and staying asleep during both training and competition. There are a number of dietary components such as nutrients and certain dietary supplements that are purported to decrease sleep latency and increase quality of sleep. While many of these interventions have been investigated in isolation, no research has examined different combinations and/or amounts of these substances to determine the resultant effects on sleep. The results of such a systematic investigation could produce an effective diet based sleep product (Sleep Drink'). The optimal components, amounts, and timing of intake of such a Sleep Drink will be explored. Additionally, the effects on sleep will be evaluated using the gold standard of sleep measurement: polysomnography.

Official Title
-----------------
Nutrients to Enhance Sleep Quality and Quantity

Conditions
-----------------
Sleepiness in Athletes

Intervention / Treatment
-----------------
* Other: Tryptophan


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 18-40 year old males Exclusion Criteria: Exclusion: Exclusion criteria will include any observed or disclosed injury, illness, sleep or health issue which may disrupt the subject's performance or endanger their health. Participants will need to complete an adult screening tool, as recommended by Exercise and Sports Science Australia (ESSA), to assess this. Blood samples will also be collected to screen for magnesium, zinc and B12 which may influence nutritional impact on sleep. If subjects score above the reference ranges for these measures, they will be excluded. The Pittsburg Sleep Quality Index (PSQI) and Stanford Sleepiness Scale (SSS) will be used to screen for sleep disturbances. If subjects score outside the reference ranges for these questionnaires, they will be excluded.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Triptophan beverage<br>Proprietary blend of nutritional interventions aimed at increasing sleepiness | Other: Tryptophan<br>* Beverage including tryptophan<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| polysomnography | The effect of the drinks will be determined primarily by polysomnography | 0-3 hours |
Deep-learning Based Classification of Spine CT

Study Overview
=================
Brief Summary
-----------------
It is time-consuming for spine surgeons or radiologists to conduct manual classifications of spinal CT, which may also be correlated with high inter-observer variance. With the development of computer science, deep learning has emerged as a promising technique to classify images from individual level to pixel level. The main of the study is to automatically identify and classify the lesions, or segment targeted structures on spinal CT with deep learning.

Detailed Description
-----------------
Computer tomography (CT) is one of the most important imaging tool to assist the diagnostic and treatment of spinal disease. Classification of specific targets (e.g. individuals, lesions, etc.) is one of the most common mission of medical image analysis. However, it is time-consuming for spine surgeons or radiologists to conduct manual classifications of spinal CT, which may also be correlated with high inter-observer variance. With the development of computer science, deep learning has emerged as a promising technique to classify images from individual level to pixel level. The main of the study is to automatically identify and classify the lesions, or segment targeted structures on spinal CT with deep learning.

Official Title
-----------------
Deep-learning Based Classification of Spine CT

Conditions
-----------------
Surgical Procedure, Unspecified

Intervention / Treatment
-----------------
* Diagnostic Test: deep learning


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: - spinal thin layer CT Exclusion Critera: medals or other implants induce artifact poor image quality

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| thin layer CT<br>Thin-layer CT will be manually labeled and used to train, validate and test deep learning algorithm. | Diagnostic Test: deep learning<br>* manually labeled samples will be used to train, validate and test deep learning algorithm, and then realize automatic classification.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| classification accuracy | classification accuracy (e.g. area under the curve, etc.) | 1 day | 
| segmentation accuracy | segmentation accuracy of multiple structures (e.g. Dice score, etc.) | 1 day |
Epidemiological Screening of IL10RA Mutation Rate in China

Study Overview
=================
Brief Summary
-----------------
The presentation of IBD in early childhood is uncommon and the monogenetic defects, especially IL-10 signaling pathway play a key role in very early onset inflammatory bowel disease (VEO-IBD). IL-10 or IL-10R deficiency associated VEO-IBD is considered a rare disorder. To date, there were about 60 cases were reported all over the word. But in our Chinese VEO-IBD Collaboration Group, 42 patients with biallelic mutations affecting IL10R genes were identified from 93 VEO-IBD patients, and the mutation sites are highly concentrated, including 83.9% (26/31) with p.R101W and 55% p.T179T (17/31) mutation, and the proportion of patients from Henan( A province of China) is higher. So we speculate that IL-10RA mutation may not be very rare, and the frequency of heterozygote subjects might be higher than suspected.

Detailed Description
-----------------
The mutation rates of p.R101W and p.T179T IL10RA in Henan newborn. Is there any clinical symptoms in children with IL-10RA-deficient? and the onset of the symptoms. Whether the intestinal permeability is normal in heterozygote subjects.

Official Title
-----------------
Epidemiological Screening of p.R101W and p.T179T IL10RA Mutation Rates in Henan Province, China

Conditions
-----------------
Digestive System Disease

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: In the study period, all newborns in the selected hospita Exclusion Criteria: Children whose guardian refused to participate in the study

Ages Eligible for Study
-----------------
Minimum Age: 24 Hours
Maximum Age: 28 Days

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The mutation rate of IL-10RA in chinese | All present mutations in IL-10RA | From birth to 3 years old | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
interleukin-10, inflammatory bowel disease
Achalasia and Dysplasia

Study Overview
=================
Brief Summary
-----------------
Patient with achalasia have a 10-50 fold increased risk to develop esophageal squamous cell carcinoma (ESCC). Early diagnosis of ESCC is essential, and detection of an earlier dysplastic stage is preferred. Endoscopic detection is however difficult and often delayed. Chromoendoscopy with Lugol dye increases detection rates dysplasia and ESCC to 91-100%. The aim of this study was therefore to evaluate a screening program using chromoendoscopy with Lugol to detect dysplasia in patients with idiopathic achalasia. A second objective is to study the relationship between foodstasis and the development op dysplasia

Official Title
-----------------
Screening for Dysplasia in Longstanding Idiopathic Achalasia: a Prospective Study

Conditions
-----------------
Dysplasia in Longstanding Achalasia, Relation Between Food Stasis and Dysplasia

Intervention / Treatment
-----------------
* Other: chromoendoscopy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: longstanding achalasia (> 15y) > 18y old informed consent Exclusion Criteria: allergy to iodine esophageal carcinoma

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: longstanding achalasia<br> | Other: chromoendoscopy<br>* chromoendoscopy (lugol stain and virtual chromoendoscopy)<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| incidence of dysplasia in patients with longstanding achalasia |  | 1 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| additive value of chromoendoscopy in comparison with lugol stain |  | 1 year | 
| relationship between food stasis and dysplasia | relationship between elevated LES pressure and dysplasia relationship between stasis on EndoFLIP and dysplasia relationship between stasis on timed barium esophagogram and dysplasia | 1 year |